Clinical Trial Update: Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing early Secukinumab 300 mg subcutaneous injections to narrow-band UVB in new-onset moderate-to-severe plaque psoriasis has completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2024-10-01